Lung Cancer Features Archive
Evidence is building to show that most people have preexisting immunity to CRISPR-based therapies. In cancer, however, it's unclear how much that matters.
Researchers are learning that roughly half of survivors live with a moderate to high degree of fear of recurrence, and teaching techniques to better cope with uncertainty is one way to help.
Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer Centers
Better collaboration between community and academic cancer centers could benefit patients.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
Immune checkpoint inhibitor pneumonitis is a potentially serious complication that may occur more in patients with lung cancer than previously suspected.
Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.
Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.
Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.
Humans are used to seeing canines used as tools in forensics — their skills are often harnessed to smell out drugs or trail a criminal. Some dogs are even used to locate household pests. The use of canines to detect lung cancer from smell alone, however, is a new prospect for oncologists and their patients.
Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
The VEGFR/EGFR inhibitor anlotinib prolonged PFS and OS in Chinese patients with NSCLC, but additional studies are needed to determine its benefit in other populations.
"Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
A preplanned exploratory analysis in a subset of patients from the phase 3 FLAURA study with CNS metastases at baseline shows "impressive" clinical activity in the CNS.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Researchers Use Artificial Intelligence to Predict Patient Survival from Pathology Images in Lung Cancer
Artificial intelligence techniques are being employed to build complex new multivariate prognostic models for patients with lung cancer and other malignancies.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
Even after an adverse event due to treatment with a checkpoint inhibitor, some patients may benefit from re-treatment with drugs from this class.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
The IASLC released guidance on the use of biopsies for the detection of EGFR and other tumor mutations in patients with NSCLC.
Two recent studies have found that signaling from other ERBB family members is necessary for survival and proliferation in KRAS-driven tumors, and that afatinib and neratinib produce an antitumor response.
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
The researchers argue that upfront next-generation sequencing should be the new standard of care.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
"BRAF-mutated NSCLC represents an emerging targetable entity among the scenario of oncogene-driven NSCLC."
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
The phase 3 study found the combination effective, regardless of tumor proportion score.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
PD-1/PD-L1 ICI can offer remarkable benefits as first- and second-line treatments for NSCLC, but 80% of patients do not respond to immunotherapy, and many of those who do respond eventually see their cancers acquire drug resistance.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.
Phase 1 trials should be considered therapeutic options for some patients.
The risk should not discourage patients with cancer from taking these potentially life-extending therapies.
Assessing tumor mutational burden may help to determine which patients will respond.
While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Efforts are underway to develop predictive molecular biomarkers that can improve patient selection for ICIs.
Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
Regular exercise can help patients with cancer deal with issues related to weight gain during treatment.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.
Study findings suggest that some clinicians are using immunotherapies in the types of patients not included in clinical trials.
Management of malignant pleural effusions should be tailored to the particular patient, depending on preference, prognosis, and variety of underlying disease.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.
One trial is evaluating whether an HDAC inhibitor, mocetinostat, in combination with a demethylating drug, guadecitabine, can boost responses to pembrolizumab in patients with advanced NSCLC.
The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.
People living in counties with strong smoke-free policies were 7.9% less likely to be diagnosed with lung cancer compared with those living in counties with no protection.
A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.
A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.
The results of this study support previous findings that psychological distress is associated with an increased risk of mortality among patients with lung cancer.
c-MET, although rarer than T790M, may be a promising therapeutic target for patients who progress on EGFR TKI therapy.
In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.
From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.
Several ongoing clinical trials are also evaluating durvalumab as a single agent or in combination with other therapies, such as tremelimumab, and as a first-line therapy.
Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.
Liquid biopsy can be useful in cases where small bronchial biopsies contain a low number of tumor cells, and the repeatability of liquid biopsies can offer new approaches for monitoring patients treated with immunotherapy.
In part 1 of a 2-part series, Bryant Furlow discusses advances in the understanding of inherited cancer syndromes and screening techniques for early tumor detection in high-risk patients.
Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.
The thromboSeq test result might not only provide information regarding lung cancer diagnostics, but potentially any other tumor types as well, and may enable tumor-type stratification.
Not conducting a second tissue biopsy could have dangerous implications for the patient according to a recent article.
Durvalumab's optimal clinical role in managing lung cancer remains unclear and more robust predictive biomarkers are needed.
As more experience with sirolimus has been gained, it began to be used "off-label" to prevent rejection in multiple transplant recipients and is now being studied in the treatment of GVHD.
While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.
SABR may be used to improve PFS, or potentially OS, among patients who have a good response to chemotherapy, targeted therapy, or immunotherapy.
The race against malware is much the same as a war between an infectious agent and a host: it's a battle between hackers and security experts — and it's not at all clear who is winning.
Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.
The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.
The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.
The development of ALK inhibitors for non-small cell lung cancer is rapidly progressing, yet acquired treatment resistance remains a key issue for a majority of patients.
Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.
Many cancers in humans are weakly immunogenic — if immunogenic at all — and overcoming this inherent property of cancer cells will be critical for the future success of cancer immunology.
Treating physicians should watch for any suspicious signs of cancer after DM is diagnosed.
Cancer Therapy Advisor asked Dr Shaw to discuss ALK- and ROS1-positive NSCLC, including currently available agents and ongoing research to develop additional targeted therapies.
Researchers are interested in identifying "exceptional responders" to cancer medications to help highlight biomarkers that will identify patients likely to respond to treatment.
If value is hard to define because it is perceived differently by different people, how can oncologists and policymakers accurately gauge cost-effectiveness?
Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of survivors, be addressed as a serious quality of life issue.
Two vaccine therapies, TG4010 and CIMAvax-EGF, show promise for treating lung cancer. Developed and approved for use in Cuba, CIMAvax-EGF is now undergoing clinical study in the United States.
While survival rates of pediatric patients with cancer are greatly improved, researchers and clinicians are evaluating how to best preserve the reproductive potential of survivors.
Cancer Therapy Advisor asked Dr Rabinowitz, founder and CEO of Natera, about the bespoke PCR technology and ongoing studies.
In this question-and-answer session, Cancer Therapy Advisor asked Dr Roberts about direct-to-consumer genomic testing for cancer risk.
Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.
Atezolizumab is the most recent in a line of immune checkpoint inhibitors approved for patients with NSCLC.
According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.
Requirements for Medicare coverage of CT lung cancer screening might be a factor for low screening rates among high-risk smokers.
According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer Institute.
Targeted and immunotherapies appear to be opening a new frontier in the management of elderly patients.
Dr Clifford Pukel, a board certified medical oncologist and CEO of the Cancer Vaccine Cancer Immunotherapy (CVCI) foundation, discusses some important moments in the history of immunotherapy.
Oncologists, drug developers, and evolutionary theorists could collaborate to design treatments and treatment combinations that are more likely to succeed given the laws of natural selection.
Clinical trial investigators who receive drug industry funding are about 3.5 times as likely to find positive results as trials led by scientists who did not receive industry payments.
Researchers recently created a tool, Treeomics, to reconstruct the evolutionary pathway of metastases and to chart subclones to their anatomical locations.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Evidence Grows Linking BIA-ALCL to Textured Surface of Some Breast Implants
- Could Cytostatic Drugs Unleash Antitumor Immunity in Lung Cancer?
- Primary End Point Not Met in Trial Testing Nivolumab Monotherapy for DLBCL
- Increased Risk of Myeloma in African Americans Driven By Higher Rates of 3 Disease Subtypes
- Fermented Dairy and Cancer
- In Mice, Lithium Shown to Reverse Dysfunction Related to Brain Tumor Compression
- Fermented Dairy and Cancer
- Immunotherapy Plus Chemotherapy May Turn Cold Tumors Hot
- Spending on Medical DTC Advertising Increased Dramatically Over the Past 20 Years
- SURTIME Trial: Surgery May Not Be Most Appropriate Frontline Treatment in mRCC